Programmed Death Receptor-1 Blocking Antibody [EPC]

98590 reported adverse events

Drugs of this class: ATEZOLIZUMAB ATEZOLIZUMAB AND HYALURONIDASE-TQJS DOSTARLIMAB NIVOLUMAB NIVOLUMAB AND HYALURONIDASE-NVHY NIVOLUMAB AND RELATLIMAB-RMBW PEMBROLIZUMAB PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH RETIFANLIMAB-DLWR TISLELIZUMAB-JSGR TORIPALIMAB-TPZI

These side effects are most commonly reported by patients taking drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 22836
1 DEATH 22537
2 OFF LABEL USE 15187
3 DIARRHOEA 12757
4 FATIGUE 11043
5 PYREXIA 9534
6 NAUSEA 7903
7 RASH 7861
8 DECREASED APPETITE 7405
9 DYSPNOEA 6173
See all common reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]

Drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 IMMUNE-MEDIATED ADRENAL INSUFFICIENCY 752 0.9435
1 IMMUNE-MEDIATED HYPOTHYROIDISM 1044 0.9255
2 IMMUNE-MEDIATED DERMATITIS 883 0.8760
3 IMMUNE-MEDIATED HEPATIC DISORDER 1683 0.8622
4 IMMUNE-MEDIATED MYOCARDITIS 1354 0.8379
5 IMMUNE-MEDIATED LUNG DISEASE 1521 0.8334
6 IMMUNE-MEDIATED HEPATITIS 1665 0.8146
7 ADRENOCORTICOTROPIC HORMONE DEFICIENCY 712 0.8109
8 FULMINANT TYPE 1 DIABETES MELLITUS 812 0.7876
9 IMMUNE-MEDIATED ENTEROCOLITIS 2831 0.7691
See all enriched reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]